EMA Shifts Gear On Patient Feedback During Drug Review
Pilot To Focus On Orphan Medicines For Which CHMP Review Is Imminent
Executive Summary
The European Medicines Agency is exploring the feasibility and utility of contacting patients’ organizations for their input as soon as its medicines evaluation committee starts reviewing a new drug.
You may also be interested in...
EMA Starts Seeking Patient Feedback Earlier For Orphan Drug MAAs
A 17-month pilot by the European Medicines Agency has highlighted the benefits of obtaining the views of patients much earlier on in the review of marketing authorization applications for orphan drugs.
Pharma Firms Told To ‘Keep Your Distance’ When Patients Come To EU CHMP Meetings
The European Medicines Agency is planning to expand the involvement of patients in benefit-risk evaluation of medicines following a successful pilot, but one EU patient group has advised drug companies not to contact patients during their visits to the agency as this could lower the value of their input.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.